Skip to main content

Young Caroline's Form 4 filing

Cumberland Pharmaceuticals Inc (CPIX) · filed Dec 30, 2024

Accession no.
0001628280-24-052610
Filed
Dec 30, 2024
Trade date
Dec 2-20, 2024
Filing delay
28 daysLate
Rule 10b5-1 plan
Checked

This filing lists 15 non-derivative transactions and 0 derivative transactions. Open-market purchases total $256.15. It was filed 28 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Young CarolineCIK 0001684087Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 2, 2024Common StockPPurchaseAcquired+15$1.33+$19.9529,679Direct
Dec 3, 2024Common StockPPurchaseAcquired+15$1.26+$18.929,694Direct
Dec 4, 2024Common StockPPurchaseAcquired+15$1.22+$18.329,709Direct
Dec 5, 2024Common StockPPurchaseAcquired+15$1.20+$1829,724Direct
Dec 6, 2024Common StockPPurchaseAcquired+15$1.20+$1829,739Direct
Dec 9, 2024Common StockPPurchaseAcquired+15$1.25+$18.7529,754Direct
Dec 10, 2024Common StockPPurchaseAcquired+7$2.48+$17.3629,761Direct
Dec 11, 2024Common StockPPurchaseAcquired+7$2.29+$16.0329,768Direct
Dec 12, 2024Common StockPPurchaseAcquired+7$2.19+$15.3329,775Direct
Dec 13, 2024Common StockPPurchaseAcquired+7$2.33+$16.3129,782Direct
Dec 16, 2024Common StockPPurchaseAcquired+10$2.21+$22.129,792Direct
Dec 17, 2024Common StockPPurchaseAcquired+10$2.12+$21.229,802Direct
Dec 18, 2024Common StockPPurchaseAcquired+10$2.19+$21.929,812Direct
Dec 19, 2024Common StockPPurchaseAcquired+4$2.33+$9.3229,816Direct
Dec 20, 2024Common StockPPurchaseAcquired+2$2.35+$4.729,818Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)